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PROSPECTIVE STUDY USING R2 MRI DEMONSTRATES HIGH IRON BUR-
DEN IN ALLOGENEIC PEDIATRIC STEM CELL TRANSPLANT RECIPIENTS
Chirnomas, D.1, Lehmann, L.2, London, W.2, Duncan, C.2, Powell, A.4,
Barry, E.3 1Yale School of Medicine, New Haven, CT; 2Dana-Farber
Cancer Institute/Children’s Hospital Boston, Boston, MA; 3Sanofi Oncol-
ogy, Cambridge, MA; 4Children’s Hospital Boston, Boston, MA
Background: Iron overload has been implicated as a key co-morbid
factor in post-stem cell transplant (SCT) outcomes. Quantifying
iron burden has been a challenge as serum iron markers are impre-
cise. MRI is a relatively new and non-invasive tool that more accu-
rately measures iron burden. We conducted a prospective study
using MRI to assess iron burden in children undergoing SCT.
Objective: To determine the prevalence of iron overload using R2
MRI of the liver in a pediatric allo SCT population both pre and
post-SCT. Relationships between excess iron and adverse outcomes
such as graft vs. host disease (GVHD), infection, and death were sec-
ondary objectives.
Methods: Children$5 years old undergoing an allo SCT at Child-
ren’s Hospital Boston from 2007-2009 were eligible for this study.
Iron overload was defined as a liver iron concentration $ 1.5 mg
iron/g dry liver tissue. A paired t-test was conducted with a 5 0.05
to compare iron load at the two specified time points. A two-sample
two-sided t-test was conducted at each time point for association
with risk factors described above with a 5 0.1. This study was IRB
approved.
Results: Twenty-eight patients were enrolled. The most common
diagnoses were Pre-B ALL (N5 7), AML (N5 6), and aplastic ane-
mia (N 5 5). Pre-SCT, 82% (95% CI: 66% - 98%) of patients had
iron overload by R2MRI. At day 100 post-SCT, 95% (95%CI: 65%
- 100%) had iron overload. The mean iron concentration (6 std er-
ror) was 4.976 3.54 mg/g dwt liver at pre-SCT and 7.556 4.37 mg/
g dwt liver at day 100 post-SCT. The day 100 post-SCTmean value
was significantly higher than the mean value at pre-SCT (2.15 mg/g
dwt liver, p\0.0001). For patients who developed an infection dur-
ing the post-SCT period, the mean iron concentration, compared
to patients who did not develop an infection, was significantly higher
at pre-SCT and at day 100 post-SCT (p5 0.029 and p5 0.0055, re-
spectively). There was no statistically significant difference in iron
concentration between patients who developed GVHD or died
and those who did not.
Conclusions: We found that a high proportion of pediatric allo
SCT patients have iron overload pre-SCT. In addition, there is a sta-
tistically significant rise in iron post-SCT (p\0.0001) and an associ-
ation with increased incidence of infection in patients with elevated
iron. Larger multi-center studies should be conducted to further ex-
amine the consequences of iron overload and evaluate potential in-
terventions in this patient population.273
ALEMTUZUMAB IS AN EFFECTIVE SALVAGE AGENT FOR REFRACTORY
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
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Background: Familial hemophagocytic lymphohistiocytosis
(FHLH) consists of several genetic disorders that compromise lym-
phocyte cytotoxicity and lead to the life-threatening hyper-inflam-
matory syndrome of HLH. Even with current standard HLH
therapy, only approximately half of patients will experience complete
resolution of disease, andmortality prior to allogeneic hematopoietic
cell transplantation (HCT) remains a significant problem. Salvage
therapies have been described only in limited case reports, and there
are no large studies of second-line therapies.
Methods:We reviewed the charts of 22 pediatric and adult patients
who received alemtuzumab for the treatment of refractory primaryHLH at our center or in consultation with our group. Patients had
received conventional therapies for a median of 8 weeks (range
2-70) prior to alemtuzumab, and treatment immediately prior to
alemtuzumab included dexamethasone (100%), etoposide (77%), cy-
closporine (36%), intrathecal hydrocortisone+/-methotrexate
(23%), methylprednisolone (9%), and rituximab (14%). Patients re-
ceived a median dose of 1mg/kg alemtuzumab (range 0.1-8.9mg/kg)
divided over a median of 4 days (range 2-10).
Results: Nineteen patients (86%) experienced a partial response.
Seventeen patients (77%) survived to undergo allogeneic HCT at
a median of 52 days following first alemtuzumab administration
(range 16-121 days). One additional patient is surviving and not cur-
rently a candidate for HCT. Patients experienced an acceptable
spectrum of complications, including CMV and adenovirus viremia.
All but 1 patient undergoing HCT survived to day +100 following
HCT.
Conclusion: Alemtuzumab is an effective salvage agent for refrac-
tory HLH, leading to disease improvement and survival to HCT
in the majority of patients.274
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC
STEM CELL RESCUE FOR CHILDRENWITH HIGH-RISK NEUROBLASTOMA.
EXPERIENCE OF A SINGLE PEDIATRIC CENTER IN BOGOTA, COLOMBIA
Chaparro, M., Estupinan, M. Fundacion HOMI Hospital de la Misericor-
dia, Bogota, Colombia
Neuroblastoma (NB) is the most common extracranial solid tu-
mor in children. Prognosis of high risk NB is extremely poor. The
use of high-dose chemotherapy with autologous hematopoietic
stem cell rescue in consolidation has resulted in improvements in
survival and appears to have the largest impact on the survival of
the high risk subset of patients although long-term event-free sur-
vival remains less than 40–50%. The aim of this retrospective study
was to analyze the outcome of childrenwith high-risk neuroblastoma
who underwent Autologous Stem Cell Transplantation (ASCT) in
a new pediatric stem cell transplant facility.
Patients andMethods: Between August 2008 to July 2011, 16 chil-
dren underwent ASCT as part of a multimodality treatment ap-
proach consisted in induction chemotherapy, surgery, HDC and
autologous stem cell rescue, radiotherapy and maintenance therapy
with 13-cis retinoid acid. The conditioning regimen used in all cases
consisted of Carboplatin (375mg/m2 for 4 days), Etoposide (300mg
/m2 for 4 days), and Melphalan (60 mg/m2 for 3 days).
Results: There were 16 patients with NB consisting of 6 males and
10 females. The median age was 4.7 years (range 1-14 years). The
median weight was 17,4kg (range 8-40kg). 12 patients had stage
IV-NB and 4 had high-risk stage III-NB. The source of stem cells
was peripheral blood in 15 patients and bone marrow in 1 patient.
The median time to Absolute Neutrophil Count. 0.5 x 10 9/L
was 13 days (range 9-35 days). Themedian time to an Absolute plate-
let count of.20 x 10 9/L was 23 days (range 9-35 days), one patient
had a graft failure who presented adequate recovery after infusion of
cryopreserved bone marrow back-up. The median follow up time
was 492 days (range 55 days-1127 days). 4 of the 16 recipients had
relapsed. At the present time, 13 patients are alive. Relapse was the
only cause of death and Transplant Related Mortality was zero.
Conclusion: we conclude that ASCT is a feasible and effective
method of treatment for patients with high risk neuroblastoma.
The inclusion of high-dose chemotherapy and autologous rescue
have improved the chances of survival of children with high risk neu-
roblastoma in developing countries allowing to reproduce the results
achieved in developed countries.275
IMPACT OF NUTRITIONAL PARAMETERS ON OUTCOME AFTER PEDIAT-
RIC HSCT
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Background: Nutritional parameters represent modifiable factors
to improve outcomes after HSCT. Pediatric studies linking weight
to survival are over 10 years old, and analyses of prealbumin (PAB)
levels have not examined the impact on survival.
Methods:We conducted a retrospective chart review of all pediatric
HSCT at our institution from 7/1/2007 to 6/30/2011 (N5 77).Wil-
coxon rank-sum test was used to compare weight characteristics as
well as PAB and albumin levels (admission, days 0, +7, +14,+28,
and +90 for albumin alone) between the autologous (auto) and allo-
geneic (allo) groups. Survival analyses utilized the Kaplan-Meier
method and the log-rank test to compare differences. Effects on sur-
vival were examined with a Cox proportional hazards model and
analyses of non-relapse mortality (NRM) incorporated competing
risks.
Results: Mean weights as % of ideal body weight at admission
were above 100% and not significantly different between the auto
and allo groups (p 5 0.80). BMI at admission was not significantly
different between the auto and allo groups (19.5 and 19.3 respec-
tively, p 5 0.97). At day +30, the auto group had greater % weight
loss than the allo group with mean weight loss of 1.7% (p 5 0.01).
In the auto group, weight loss at day +30 was associated with sig-
nificantly worse day +100 and 1 yr survival compared to those who
had weight gain (p 5 0.03). The lowest median PAB level was 13.8
mg/dL on day 0 for allo patients and 12.2 mg/dL on day +7 for
auto patients. Similarly, the lowest median albumin level was 2.9
g/dL on day 0 for allo patients and 2.8 g/dL on day +7 for auto pa-
tients. Differences between groups at these time points were statis-
tically significant (p\0.05). Univariate analyses identified PAB
levels below 15 mg/dL at day +7 as significantly decreasing day
+100 and 1 yr survival in the allo group (p 5 0.0003). Additionally,
allo patients with a PAB level below 12 mg/dL at any time between
day 0 to +14 had worse day +100 and 1 yr survival (p 5 0.023).
Multivariate analysis of the combined groups demonstrated a signif-
icant impact of decreased PAB levels between day 0 to +14 on
NRM, with a hazard ratio of 0.85 (95%CI 0.76-0.96, p 5 0.006).
Accordingly, this represents an increase in NRM risk of 120%
per 5 mg/dL decrease in PAB.
Conclusion: Nutritional support should be maximized early in the
transplant course. As PAB is decreased in the setting of inflamma-
tion, future studies should prospectively evaluate PAB in conjunction
with inflammatory markers.276
MOYAMOYA SYNDROME TREATED WITH ENCEPHALODUROARTERIOSY-
NANGIOSIS FOLLOWED BY HEMATOPOIETIC CELL TRANSPLANTATION
IN PATIENTS WITH SICKLE CELL DISEASE
Klein, O.1, Walters, M.2, George, D.3, Chu, R.4, Goodrich, J.T.5,
Roman, E.1, Schubert, R.6, Del Toro, G.1 1Mount Sinai School of Medi-
cine, New York, NY; 2Children’s Hospital & Research Center, Oakland,
Oakland, CA; 3Columbia University College of Physicians and Surgeons,
New York, NY; 4Children’s Hospital of Michigan, Detroit, MI; 5Child-
ren’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx,
NY; 6New York Methodist Hospital, Brooklyn, NYTable 1. Supplemental Patient Data
Patient
Presenting Symptoms
of Initial CNS Event
Age at Diagnosis of
Moyamoya Syndrome Age at EDA
1 Seizures 11 years 6 months 12 years 2 mont
2 Visual changes 13 years 2 months Two-Step Proced
4 months and
3 Seizures 2 years 6 months 4 years 6 month
4 Left-Sided Hemiparesis 3 years 6 years 6 month
5 Seizures, Personality
Changes
7 years 6 months Two-Step Proced
years 10 mon
years 11 mon
6 Eye pain 6 years 11 years 9 montBackground: Patients with sickle cell disease (SCD) have a high risk
of intracranial large vessel vasculopathy, leading to a proliferation of
microvasculature at the base of the brain known as moyamoya syn-
drome. This confers a high risk of intraventricular hemorrhage
and permanent neurologic deficits. Moyamoya syndrome can be
treated surgically with a revascularization procedure called encepha-
loduroarteriosynangiosis (EDAS), which has been shown to decrease
but not eliminate the risk of stroke. Hematopoietic cell transplanta-
tion (HCT) from a compatible sibling is the most effective way of
preventing central nervous system (CNS) complications in SCD pa-
tients at risk for CNS events. There have been several reports of pa-
tients with SCD and moyamoya syndrome undergoing EDAS
successfully; however, there have been no reports of these patients
undergoing EDAS followed by HCT.
Results:We report six pediatric cases of patients with SCDwho de-
veloped moyamoya syndrome, all of whom underwent EDAS fol-
lowed by HCT. All patients underwent EDAS procedure
successfully. One patient experienced a stroke less than a month after
EDAS. Another patient developed a foot-drop post-EDAS, though
imaging did not show any new areas of infarct. All patients under-
went HLA-matched sibling-donor HCT. The chronic transfusion
therapy was successfully discontinued in the two patients who had
been on it prior to treatment. Post-transplant, one patient developed
seizures, with imaging consistent with possible infarct; the patient
was placed on antiepileptics and has not had subsequent seizures.
In all follow-up imaging, there has been no progression of the pa-
tients’ moyamoya syndrome.
Conclusion:These are the first reported cases of EDAS successfully
followed by HCT in patients with SCD and moyamoya syndrome.
Five of the six patients had no further CNS events, and all remained
neurologically stable, with no progression of their moyamoya syn-
drome. HCT is the standard of care in patients with SCD at risk
for CNS complications, leading to excellent stroke-free survival
rates. Patients with moyamoya syndrome and SCD are at high risk
of developing CNS complications. Transplant-eligible SCD pa-
tients who develop moyamoya syndrome may benefit from EDAS
prior to HCT in order to minimize CNS complications. Further in-
vestigation by way of an international, multicenter prospective study
is needed to determine the long-term outcome and potential benefits
of this therapeutic combination.277
COMPARISON OF SURVIVAL AND INCIDENCE OF GRAFT VERSUS HOST
DISEASE IN FULLY MATCHED, SINGLE C MISMATCHED AND OTHER MIS-
MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTS IN A PEDIATRIC POPULATION
Liney, D.1, Lee,M.A.2, Sun, P.1, London,W.B.1, Lehmann, L.E.2 1Dana
Farber Cancer Institute, Boston, MA; 2Dana- Farber/Children’s Hospital
Cancer Care, Boston, MA
It is well understood that undergoing hematopoietic stem cell
transplant (HSCT) froman unrelated (URD) compared to amatched
sibling donor (MSD) results in increased graft versus host disease
(GVHD) and for the pediatric population this often but not always
negatively impacts overall survival. In the current era of high resolu-
tion Class I / Class II typing there is a lack of clarity about the impactS Procedure Age at HCT Post-HCT Complications
hs 12 years 8 months Seizure, Possible Left Middle
Cerebral Artery Infarct
ure: 13 years
13 years 7 months
13 years 9 months None
s 5 years 6 months None
s 8 years 6 months None
ure: 8
ths and 8
ths
13 years None
hs 13 years 6 months None
